{
    "1734545581022822901": {
        "attachments": {
            "media_keys": [
                "3_1734545578678276096"
            ]
        },
        "author_id": "62465691",
        "created_at": "2023-12-12T12:07:47.000Z",
        "edit_history_tweet_ids": [
            "1734545581022822901"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 152,
                    "normalized_text": "VLPs",
                    "probability": 0.6972,
                    "start": 149,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 10,
                    "start": 0,
                    "tag": "Investors"
                },
                {
                    "end": 17,
                    "start": 11,
                    "tag": "Media"
                },
                {
                    "end": 111,
                    "start": 92,
                    "tag": "VaccineDevelopment"
                }
            ],
            "mentions": [
                {
                    "end": 55,
                    "id": "1174396389196881921",
                    "start": 46,
                    "username": "icosavax"
                }
            ],
            "urls": [
                {
                    "display_url": "learn.az/6019RO8tH",
                    "end": 280,
                    "expanded_url": "https://learn.az/6019RO8tH",
                    "start": 257,
                    "status": 200,
                    "unwound_url": "https://www.astrazeneca.com/content/dam/az/PDF/2023/AstraZeneca-Icosavax.pdf?utm_source=twitter&utm_medium=project+isochrone&utm_term=12174&utm_content=opportunistic",
                    "url": "https://t.co/5rhAh0MKyN"
                },
                {
                    "display_url": "pic.twitter.com/AHDxFyZj5N",
                    "end": 304,
                    "expanded_url": "https://twitter.com/AstraZeneca/status/1734545581022822901/photo/1",
                    "media_key": "3_1734545578678276096",
                    "start": 281,
                    "url": "https://t.co/AHDxFyZj5N"
                }
            ]
        },
        "id": "1734545581022822901",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 1,
            "impression_count": 4388,
            "like_count": 24,
            "quote_count": 2,
            "reply_count": 5,
            "retweet_count": 8
        },
        "text": "#Investors #Media: \n\nOur agreement to acquire @Icosavax aims to unlock new possibilities in #VaccineDevelopment by pioneering the next generation of VLPs to address high unmet need in infectious diseases. Additional important information can be found here: https://t.co/5rhAh0MKyN https://t.co/AHDxFyZj5N"
    }
}